Prevalence of anti-cyclic citrullinated peptide antibodies in patients with spondyloarthritis: A retrospective study. Issue 2 (4th March 2021)

• Record Type: Journal Article
• Authors: Yamazaki, Hiromitsu; Kuroiwa, Takanori; Shinmura, Ken; Yukioka, Masao; Murata, Norikazu
• Is Part Of: Modern rheumatology. Volume 31:Issue 2(2021)
• Page Start: 458
• Page End: 461
• Publication Date: 2021-03-04
• Subjects: CCP antibodies -- citrullinated protein antibodies -- psoriatic arthritis -- rheumatoid arthritis -- spondyloarthritis; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1080/14397595.2020.1761070
• Languages: English
• ISSNs: 1439-7595

Abstract

Abstract: Objectives: Anti-cyclic citrullinated peptide (CCP) antibodies are frequently detected in the sera of patients with rheumatoid arthritis (RA). However, recent studies have revealed a potentially high prevalence rate of these antibodies in patients with other rheumatic disorders, causing confusion while diagnosing RA. Therefore, this study aimed to evaluate the positive rate of anti-CCP antibodies in other chronic arthritis diseases focusing on patients with spondyloarthritis (SpA). Methods: A total of 109 patients who were diagnosed with SpA at Yukioka Hospital from 1993 to 2018 were included in this retrospective analysis, including patients with ankylosing spondylitis (AS); psoriatic arthritis (PsA); synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome (SAPHO); undifferentiated spondyloarthritis (uSpA); reactive arthritis (ReA); and inflammatory bowel disease-associated SpA (IBD). Results: Overall, 15.3% (16/109) of patients with SpA were positive for anti-CCP antibodies, including 2.3% (1/43) in AS, 23.1% (3/13) in SAPHO, 35.0% (7/20) in PsA, 14.8% (4/27) in uSpA, 0% (0/3) in ReA, and 33.3% (1/3) in IBD. Conclusion: PsA patients have a significantly higher prevalence rate of positive anti-CCP antibodies among SpA patients, and the positive rates in SAPHO and uSpA were also high. These findings provide insight into the heterogeneity of SpA with relevance for RA differential diagnosis.